This week, the FDA granted approval to Sanofi SNY and Regeneron’s REGN blockbuster drug, Dupixent, for its sixth indication. The FDA also granted priority review designation to AstraZeneca’s AZN label...
AbbVie ABBV announced in a regulatory filing that it is lowering its previously issued guidance for 2024 adjusted earnings per share by 4 cents per share to account for acquired in-process research and...
Eli Lilly and Company LLY announced a significant $4.5 billion investment for the establishment of the Lilly Medicine Foundry in Indiana to advance drug production and innovation. This facility will enable...
Its alliance with a successful foreign biotech could be decisive for the stock.
This week, J&J JNJ filed for voluntary bankruptcy for the third time in an attempt to bring an end to thousands of lawsuits related to its talc products. Pfizer PFE said it is withdrawing its sickle-cell...
The drug and biotech sector has outperformed the broader equity market this year, backed by the launch of promising new medicines, pipeline successes and an increase in merger and acquisition (M&A) activity....
AstraZeneca AZN and Japanese partner Daiichi Sankyo announced that their antibody-drug conjugate, datopotamab deruxtecan (Dato-DXd), failed to achieve statistical significance in the final overall survival...
AbbVie ABBV announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the regulatory filing seeking approval for its ovarian cancer drug Elahere (mirvetuximab...
This week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS Kisqali for early breast cancer, Merck’s MRK Keytruda for malignant pleural...
Sanofi’s SNY stock has gained 22.7% in the past three months compared with an increase of 2.9% for the industry. The stock has also outperformed the sector and the S&P 500 index as seen in the chart...